Literature DB >> 20725057

Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.

Stephen T Turner1, Gary L Schwartz, Arlene B Chapman, Amber L Beitelshees, John G Gums, Rhonda M Cooper-DeHoff, Eric Boerwinkle, Julie A Johnson, Kent R Bailey.   

Abstract

BACKGROUND: Age and race categories or renin profiling have been recommended to predict blood pressure responses to monotherapy with a beta-blocker or thiazide diuretic. Whether these or other characteristics predict blood pressure responses when the drugs are administered as add-on therapy is uncertain.
METHODS: We evaluated predictors of blood pressure response in 363 men and women < or =65 years of age with primary hypertension (152 blacks, 211 whites), 86 of whom (24%) were untreated and 277 of whom (76%) were withdrawn from previous antihypertensive drugs before randomization to either atenolol followed by addition of hydrochlorothiazide (N = 180) or hydrochlorothiazide followed by addition of atenolol (N = 183). Responses were determined by home blood pressure averages before and after each drug administration. Race, age, plasma renin activity, and other characteristics including pretreatment blood pressure levels were incorporated into linear regression models to quantify their contributions to prediction of blood pressure responses.
RESULTS: Plasma renin activity and pretreatment blood pressure level consistently contributed to prediction of systolic and diastolic responses to each drug administered as mono- and as add-on therapy. Higher plasma renin activity was consistently associated with greater blood pressure responses to atenolol and lesser responses to hydrochlorothiazide. The predictive effects of plasma renin activity were statistically independent of race, age, and other characteristics.
CONCLUSIONS: Plasma renin activity and pretreatment blood pressure level predict blood pressure responses to atenolol and hydrochlorothiazide administered as mono- and as add-on therapy in men and women < or =65 years of age.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20725057      PMCID: PMC2941699          DOI: 10.1038/ajh.2010.98

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  37 in total

Review 1.  Renin profiles. The unfulfilled promises.

Authors:  N M Kaplan
Journal:  JAMA       Date:  1977-08-15       Impact factor: 56.272

2.  Unexpected pressor responses to propranolol in essential hypertension. An interaction between renin, aldosterone and sympathetic activity.

Authors:  J I Drayer; H J Keim; M A Weber; D B Case; J H Laragh
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

3.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

4.  Antihypertensive action of propranolol. Specific antirenin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension.

Authors:  F R Bühler; J H Laragh; E D Vaughan; H R Brunner; H Gavras; L Baer
Journal:  Am J Cardiol       Date:  1973-09-20       Impact factor: 2.778

5.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

6.  Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. A cooperative study.

Authors: 
Journal:  JAMA       Date:  1977-01-17       Impact factor: 56.272

7.  Renin profiling in hypertension and its use in treatment with propranolol and chlorthalidone.

Authors:  J W Woods; A W Pittman; C C Pulliam; E E Werk; W Waider; C A Allen
Journal:  N Engl J Med       Date:  1976-05-20       Impact factor: 91.245

8.  Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

9.  Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J I Drayer; R P White; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

10.  Comparison of propranolol or hydrochlorothiazide alone for treatment of hypertension. III. Evaluation of the renin-angiotensin system.

Authors:  E D Freis; B J Materson; V Flamenbaum
Journal:  Am J Med       Date:  1983-06       Impact factor: 4.965

View more
  31 in total

Review 1.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

2.  Malignant hypertension and interferon-beta: a case report.

Authors:  S Rubin; A Lacraz; V Galantine; P Gosse
Journal:  J Hum Hypertens       Date:  2013-09-26       Impact factor: 3.012

3.  Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses).

Authors:  Caitrin W McDonough; Oyunbileg Magvanjav; Ana C C Sá; Nihal M El Rouby; Chintan Dave; Amelia N Deitchman; Marina Kawaguchi-Suzuki; Wenbin Mei; Yong Shen; Ravi Shankar Prasad Singh; Mohamed Solayman; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Amy Webb; Steven E Scherer; Wolfgang Sadee; Stephen T Turner; Rhonda M Cooper-DeHoff; Yan Gong; Julie A Johnson
Journal:  Circ Genom Precis Med       Date:  2018-04

Review 4.  Assessment and management of resistant hypertension.

Authors:  Raj S Padwal; Simon Rabkin; Nadia Khan
Journal:  CMAJ       Date:  2014-08-18       Impact factor: 8.262

5.  Pharmacogenomic Genome-Wide Meta-Analysis of Blood Pressure Response to β-Blockers in Hypertensive African Americans.

Authors:  Yan Gong; Zhiying Wang; Amber L Beitelshees; Caitrin W McDonough; Taimour Y Langaee; Karen Hall; Siegfried O F Schmidt; Robert W Curry; John G Gums; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Hypertension       Date:  2016-01-04       Impact factor: 10.190

6.  PTPRD gene associated with blood pressure response to atenolol and resistant hypertension.

Authors:  Yan Gong; Caitrin W McDonough; Amber L Beitelshees; Nihal El Rouby; Timo P Hiltunen; Jeffrey R O'Connell; Sandosh Padmanabhan; Taimour Y Langaee; Karen Hall; Siegfried O F Schmidt; Robert W Curry; John G Gums; Kati M Donner; Kimmo K Kontula; Kent R Bailey; Eric Boerwinkle; Atsushi Takahashi; Toshihiro Tanaka; Michiaki Kubo; Arlene B Chapman; Stephen T Turner; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Hypertens       Date:  2015-11       Impact factor: 4.844

Review 7.  Plasma renin testing to guide antihypertensive therapy.

Authors:  Anthony J Viera; Curt D Furberg
Journal:  Curr Hypertens Rep       Date:  2015-01       Impact factor: 5.369

Review 8.  Hypertension Across a Woman's Life Cycle.

Authors:  Nanette K Wenger; Anita Arnold; C Noel Bairey Merz; Rhonda M Cooper-DeHoff; Keith C Ferdinand; Jerome L Fleg; Martha Gulati; Ijeoma Isiadinso; Dipti Itchhaporia; KellyAnn Light-McGroary; Kathryn J Lindley; Jennifer H Mieres; Mary L Rosser; George R Saade; Mary Norine Walsh; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2018-04-24       Impact factor: 24.094

Review 9.  Rational use of antihypertensive medications in children.

Authors:  Michael A Ferguson; Joseph T Flynn
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

Review 10.  Hypertension pharmacogenomics: in search of personalized treatment approaches.

Authors:  Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Nat Rev Nephrol       Date:  2015-11-23       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.